Hence, only two subgroups appear to be suitable candidates for reduced treatment: (1) B-ALL patients with a favorable genotype (ETV6-RUNX1 positivity or hyperdiploidy > 50) who achieve an early negative MRD status (10–4) by conventional methods or (2) other NCI standard-risk B-ALL patients with negative MRD by high-throughput sequencing ( < 10–5) at the end of remission induction. Here, RUNX1 is linked to acute lymphoblastic leukemia.